Posted by Michael Wonder on 06 Jul 2017
HAS publishes TC opinion on Olumiant
6 July 2017 - The medical service rendered by Olumiant (baricitinib) is important.
The Transparency Committee considers that Olumiant does not have an additional benefit in the management of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or are intolerant to one or more of the current treatments (ASMR = V).
